Recovery from Refractory Chronic Fatigue Syndrome with CBT and Modafinil

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2021 Mar 23

PMID 33753384

Citations 1

Authors

Himanshu Garg

Maggie Douglas

Gordon Douglas Turkington

Douglas Turkington

Affiliations

Soon will be listed here.

Abstract

Many patients with chronic fatigue syndrome (CFS) fail to derive benefit from evidence-based treatments such as cognitive-behavioural therapy (CBT) and graded exercise therapy leading to permanent disability. To discover whether a repeat prescription of modafinil might potentiate the benefits of CBT leading to social recovery as defined by 2 or more point improvement in energy and muscular pain/concentration and return to work or full-time training. Three patients with treatment-resistant CFS (mean duration 17.66 years) treated with modafinil and CBT in a Liaison Psychiatry clinic were retrospectively reviewed. Progress was reviewed at baseline, 4-6 months and 10-24 months. Patients rated their fatigue, pain and concentration using 10-point Likert scales. 2/3 achieved clinically meaningful improvements in energy and pain/concentration and 3/3 achieved social recovery. Modafinil, when prescribed over the medium term, would appear to be a potentially useful potentiating agent when added to CBT.

Citing Articles

Patient experiences with requests for medical assistance in dying: Perspectives of those with complex chronic conditions.

Fruhstorfer C, Kelly M, Spiegel L, Baylis P, Dembo J, Wiebe E Can Fam Physician. 2024; 70(1):41-47.

PMID: 38262757 PMC: 11126284. DOI: 10.46747/cfp.700141.

References

Ballon J, Feifel D . A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006; 67(4):554-66. DOI: 10.4088/jcp.v67n0406. View

Deale A, Chalder T, Wessely S . Illness beliefs and treatment outcome in chronic fatigue syndrome. J Psychosom Res. 1998; 45(1):77-83. DOI: 10.1016/s0022-3999(98)00021-x. View

Ballard R . Management of patients with obstructive sleep apnea. J Fam Pract. 2008; 57(8 Suppl):S24-30. View

Marshall R, Paul L, Wood L . The search for pain relief in people with chronic fatigue syndrome: a descriptive study. Physiother Theory Pract. 2010; 27(5):373-83. DOI: 10.3109/09593985.2010.502554. View

Reeves W, Jones J, Maloney E, Heim C, Hoaglin D, Boneva R . Prevalence of chronic fatigue syndrome in metropolitan, urban, and rural Georgia. Popul Health Metr. 2007; 5:5. PMC: 1904178. DOI: 10.1186/1478-7954-5-5. View

Clarke J, James S . The radicalized self: the impact on the self of the contested nature of the diagnosis of chronic fatigue syndrome. Soc Sci Med. 2003; 57(8):1387-95. DOI: 10.1016/s0277-9536(02)00515-4. View

Scammell T, Estabrooke I, McCarthy M, Chemelli R, Yanagisawa M, Miller M . Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000; 20(22):8620-8. PMC: 6773149. View

Hutchinson C, Maltby J, Badham S, Jason L . Vision-related symptoms as a clinical feature of chronic fatigue syndrome/myalgic encephalomyelitis? Evidence from the DePaul Symptom Questionnaire. Br J Ophthalmol. 2013; 98(1):144-5. DOI: 10.1136/bjophthalmol-2013-304439. View

Edmonds M, McGuire H, Price J . Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2004; (3):CD003200. DOI: 10.1002/14651858.CD003200.pub2. View

10.

Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J . Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol. 2001; 248(7):632-4. DOI: 10.1007/s004150170148. View

11.

Perez de la Mora M, Aguilar-Garcia A, Ramirez-Ramirez R, Mendez-Franco J, Rambert F, Fuxe K . Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Neurosci Lett. 1999; 259(3):181-5. DOI: 10.1016/s0304-3940(98)00905-7. View

12.

Rammohan K, Rosenberg J, Lynn D, Blumenfeld A, Pollak C, Nagaraja H . Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002; 72(2):179-83. PMC: 1737733. DOI: 10.1136/jnnp.72.2.179. View

13.

Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L . Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005; 64(7):1139-43. DOI: 10.1212/01.WNL.0000158272.27070.6A. View

14.

Anderson V, Jason L, Hlavaty L, Porter N, Cudia J . A review and meta-synthesis of qualitative studies on myalgic encephalomyelitis/chronic fatigue syndrome. Patient Educ Couns. 2011; 86(2):147-55. PMC: 3229648. DOI: 10.1016/j.pec.2011.04.016. View

15.

Li Y, Gao X, Sakurai T, van den Pol A . Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron. 2002; 36(6):1169-81. DOI: 10.1016/s0896-6273(02)01132-7. View

16.

Ferraro L, Antonelli T, OConnor W, Tanganelli S, Rambert F, Fuxe K . Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1998; 42(12):1181-3. DOI: 10.1016/s0006-3223(97)00353-3. View

17.

Collin S, Crawley E, May M, Sterne J, Hollingworth W . The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study based on the CFS/ME national outcomes database. BMC Health Serv Res. 2011; 11:217. PMC: 3184626. DOI: 10.1186/1472-6963-11-217. View

18.

Van Houdenhove B, Pae C, Luyten P . Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?. Expert Opin Pharmacother. 2010; 11(2):215-23. DOI: 10.1517/14656560903487744. View

19.

Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A . The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994; 121(12):953-9. DOI: 10.7326/0003-4819-121-12-199412150-00009. View

20.

Stone E, Cotecchia S, Lin Y, Quartermain D . Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity. Synapse. 2002; 46(4):269-70. DOI: 10.1002/syn.10127. View